Clinical trial · Observational
Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)
NCT02300532CI-TRIAL-00026172completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Post-marketing surveillance to investigate the clinical safety and effectiveness in patients of all implantation of Gliadel with malignant glioma in the actual medical setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Glioma | Malignant Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cohort 1
- description
- Patients with diagnosed malignant glioma treated by surgery, implanted Gliadel wafers 7.7mg
- interventionNames
- Other: No intervention
Primary outcomes (1)
- measure
- Number of Adverse Events/Serious Adverse Events
- timeFrame
- Up to 3 months
Secondary outcomes (1)
- measure
- Survival rate
- timeFrame
- Up to 1 year
- description
- Survival rate of subjects measured up to 1 year after implantation of Gliadel
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion criteria: * All-patient of Gliadel implantation Exclusion criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.